3 completed, 2 active not recruiting, 1 recruiting, 1 terminated. 7 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Active not recruiting 2, Recruiting 1, Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Chronic Lymphoid Leukemia: new trials by email Literature Review of Chronic Lymphoid Leukemia trials Research Report on Chronic Lymphoid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Acalabrutinib in Very Old or Frail Patients With Treatment-naïve or Relapsed/Refractory CLL Acalabrutinib - Chronic Lymphoid Leukemia | Phase 2 | Completed | German CLL Study Group | 53 | 2021-06-01 | 2025-06-08 |
| Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL Bendamustine, Obinutuzumab, Zanubrutinib - Chronic Lymphoid Leukemia | Phase 2 | Active not recruiting | German CLL Study Group | 42 | 2020-10-01 | 2026-08-20 |
| The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide Rituximab, Chemotherapy, Tenofovir alafenamide - Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia | Phase 2 | Terminated | Gruppo Italiano Malattie EMatologiche dell'Adulto | 5 | 2020-07-07 | 2025-02-27 |
| Preemptive Therapy for High Risk Chronic Lymphoid Leukemia Stage A Venetoclax - Chronic Lymphoid Leukemia | Phase 2 | Active not recruiting | French Innovative Leukemia Organisation | 82 | 2019-05-22 | 2025-11-26 |
| Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning Thymoglobulin, Melphalan, Fludarabine - Acute Myeloid Leukemia in Remission, Myelodysplastic Syndromes | Phase 2 | Recruiting | University of Liege | 114 | 2019-02-04 | 2022-10-12 |
| Sequential Regimen of Bendamustin-Debulking Followed by Obinutuzumab, Acalabrutinib and Venetoclax in Patients With Relapsed/Refractory CLL Bendamustine, Obinutuzumab, Acalabrutinib - Chronic Lymphoid Leukemia | Phase 2 | Completed | German CLL Study Group | 46 | 2019-01-14 | 2024-12-30 |
| A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies ABT-263 - Chronic Lymphoid Leukemia, Lymphoid Malignancies | Phase 1 / Phase 2 | Completed | AbbVie (prior sponsor, Abbott) | 81 | 2006-11-01 | 2021-08-02 |
Leukemia, B-Cell (7) · Lymphoma, Non-Hodgkin (2) · Graft vs Host Disease (1) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Follicular (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Mantle-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Lymphoma, T-Cell, Peripheral (1) · Multiple Myeloma (1) · Mycosis Fungoides (1) · Myelodysplastic Syndromes (1) · Myeloproliferative Disorders (1)
Hematologic Diseases (7) · Hemic and Lymphatic Diseases (7) · Immune System Diseases (7) · Immunoproliferative Disorders (7) · Leukemia (7) · Leukemia, Lymphoid (7) · Lymphatic Diseases (7) · Lymphoproliferative Disorders (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Lymphoma (3) · Lymphoma, B-Cell (2) · Blood Protein Disorders (1) · Bone Marrow Diseases (1) · Cardiovascular Diseases (1)
venetoclax (3) · Bendamustine Hydrochloride (2) · acalabrutinib (2) · obinutuzumab (2) · Cyclophosphamide (1) · Drug Therapy (1) · Melphalan (1) · Rituximab (1) · fludarabine (1) · navitoclax (1) · tenofovir alafenamide (1) · thymoglobulin (1) · zanubrutinib (1)
German CLL Study Group (3) · AbbVie (prior sponsor, Abbott) (1) · French Innovative Leukemia Organisation (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · University of Liege (1)
Germany (3) · Austria (1) · Belgium (1) · Canada (1) · France (1) · Italy (1) · United States (1)
Paula Cramer, Dr. med. (2) · Alessandra Micozzi (1) · Barbara Eichhorst, Prof. (1) · Giuseppe Gentile (1) · Mack Mabry, MD (1)
PMID 33236943, PMID 33559286, PMID 35594173, PMID 35988545, PMID 38620072, PMID 39883943, PMID 40906922
2017 (1), 2018 (1), 2023 (1)